Scarica l'app Stockscreener
27.05
2.52%
-0.70
Dopo l'orario di chiusura:
26.76
-0.29
-1.07%
Precedente Chiudi:
$27.75
Aprire:
$27.4
Volume 24 ore:
1.44M
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.71B
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-7.771
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
-2.21%
1M Prestazione:
+56.81%
6M Prestazione:
-9.47%
1 anno Prestazione:
+104.15%
Intervallo 1D:
$26.37
$27.74
Intervallo di 1 settimana:
$25.68
$29.83
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
27.05 | 1.75B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE) - Stock Titan
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
What Just Happened with uniQure's Earnings and FDA Update - Kavout
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
uniQure N.V. (NASDAQ: QURE) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Insider Monkey
Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing - marketscreener.com
uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options - Stock Titan
State Street (QURE) affiliates disclose 3.6% ownership, 2.26M shares - Stock Titan
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play - Seeking Alpha
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
uniQure NV(QURE) Stock Options Chain | Quotes & News - Moomoo
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed - Stock Titan
uniQure N.V.Ordinary Shares (NQ: QURE - FinancialContent
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations - DirectorsTalk Interviews
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UniQure (QURE) Q1 2026 Loss Of US$53.5m Tests Bullish Growth Narrative - Sahm
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - Moomoo
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
QURE: AMT-130 advances toward U.K. MAA, revenue rises, and cash runway extends into H2 2029 - TradingView
UniQure 1Q Loss/Shr 85c >QURE - Moomoo
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
QURE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
uniQure upgraded by RBC Capital Mkts with a new price target - Quantisnow
Q1 2026 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - The Manila Times
UniQure: Q1 Earnings Snapshot - Barchart.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
Press Release: UniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - Moomoo
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure Nv Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
May 08 '26 |
Sale |
25.06 |
45,000 |
1,127,500 |
169,669 |
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):